ABSTRACT:
Alzheimer disease (AD) chronic neurodegenerative disease. Beta amyloid and tau neuropathy associated with this disease. New drug therapy deals with AREA, DIED etc. The in vitro and in vivo study shows Aducanumab was the first treatment to address an underlying cause of the disease. This removes sticky depositions of amyloid plaques. Alzheimer's neuropathology the superfrontal cortex suffer from atrophy and loss of neurones, which occurs inflammation and deposition of amyloid plaques and bundles of connective tissue and abnormal set of protein fragments. The monoclonal part of the drug attacks the aggregated depositions. Gantenerumab & Solanezumab also are tested for curing for this disease. There much model like 2D and 3D and various cultural model by which the AD cure process can be reached. A neuron is unit of the brain function, which contains an excess amount of polyunsaturated (fatty) acids. It can react with ROS, which can deals with lipid peroxidation response and cell apoptosis, in addition, low glutathione to neurons and is major causes of oxidative stress injure Modelling has been formed by stem cells, vascularised organ. Advanced models are used to understand better neurodegeneration, and potential therapies. In this review we can say that the current progress of new therapeutics like lipid metabolism, inflammation, and disease customize genes to AD in preclinical and clinical research. It’seeming that higher dose are worked in AD patients but lower dose causes AREA. ARIA can successfully cured in most of the patients who engaged themselves in important tests without stopping the treatment.
Cite this article:
Twinkle Pal, Mayurika Das. Review of Alzheimer’s Disease’s Animal Model with it’s Pathophysiology and Drug Discovery. Asian Journal of Research in Pharmaceutical Sciences. Sci. 2024; 14(1):34-2 doi: 10.52711/2231-5659.2024.00006
Cite(Electronic):
Twinkle Pal, Mayurika Das. Review of Alzheimer’s Disease’s Animal Model with it’s Pathophysiology and Drug Discovery. Asian Journal of Research in Pharmaceutical Sciences. Sci. 2024; 14(1):34-2 doi: 10.52711/2231-5659.2024.00006 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2024-14-1-6
REFERENCE:
1. Maryam Heydari, Farideh Razban, Tayebeh Mirzaei, Shahin Heidari. The Effect of Problem Oriented Coping Strategies Training on Quality of Life of Family Caregivers of Elderly with Alzheimer. Asian J. Nur. Edu. and Research.2017; 7(2): 168-172.
2. Dhanya George, Anu Jacob Kachappillil. The level of Memory Impairment among elderly in a rural community of Ernakulam District. Asian J. Nursing Education and Research. 2020; 10(1): 107-109.
3. Jismi Jigu, Jitty Jose, Leema Thomas, Shinu Sherry, Vincy Varghese, Sheeja S. A Study to Assess the Knowledge regarding Alzheimer's Disease among people above 45 years of age in selected areas at kollam. Asian Journal of Nursing Education and Research. 2022; 12(2):224-6.
4. Rahul P. Jadhav, Manohar D. Kengar, Omkar V. Narule, Vikranti W. Koli, Suraj B. Kumbhar. A Review on Alzheimer’s Disease (AD) and its Herbal Treatment of Alzheimer’s Disease. Asian J. Res. Pharm. Sci2019; 9(2):112-122.
5. P Vijayalakshmi, R Radha. In vitro Anti-Alzheimer and Anti-Oxidant activity of the Peels of Citrus maxima fruits. Journal of Pharmacology and Pharmacodynamics. 2016; 8(1): January -March, 17-22
6. Sampoornam.W, Basil V. Kuriakose. Effectiveness of Visual Images Mnemonic Training on Memory among Alzheimer’s Disease Patients at Alzheimer’s and related Disorders society of India, Cochin, Kerala. Int. J. of Advances in Nur. Management. 2019; 7(2):95-96
7. Patel Minesh. A Review on Importance of Artificial Intelligence in Alzheimer’s Disease and it’s Future Outcomes for Alzheimer’s Disease. Research Journal of Pharmacology and Pharmacodynamics.2022; 14(1):13-2.
8. Vasudev Pai, Chandrashekar K. S, C. S. Shreedhara, Aravinda Pai. In-Silico and In-Vitro correlation studies of natural β-secretase inhibitor: An approach towards Alzheimer’s Disease. Research J. Pharm. and Tech 2017; 10(10):3506-3510.
9. Chandni Naidu, Dhanush Kumar, N Maheswari, M Sivagami. Prediction of Alzheimer’s Disease using Brain Images. Research J. Pharm. and Tech 2018; 11(12): 5365-5368.
10. Dhinakaran S, Tamilanban T, Chitra V. Targets for Alzheimer’s Disease. Research J. Pharm. and Tech. 2019; 12(6):3073-3077.
11. Rahul P. Pol, N. S. Naikwade, R. J. Dias. Targeting Aβ protein in Alzheimer’s Disease. Research J. Pharm. and Tech 2020; 13(2):1004-1008.
12. Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW. Tau, tangles, and Alzheimer’s disease. Biochim Biophys Acta - Mol Basis Dis. 2005; 1739(2):216–23.
13. Qi S, Dong J, Xu Z, Cheng X, Zhang W. PROTAC : An Effective Targeted Protein Degradation Strategy for Cancer Therapy. 2021; 12(May):1–13.
14. Schwestermann T, Eglinton TI, Haghipour N, Mcnichol AP, Ikehara K, Strasser M. Event-dominated transport, provenance, and burial of organic carbon in the Japan Trench. Earth Planet Sci Lett [Internet]. 2021; 563:116870. Available from: https://doi.org/10.1016/j.epsl.2021.116870
15. Brown CR, Eskin JA, Hamperl S, Griesenbeck J, Jurica MS, Boeger H. Chapter 9 Chromatin Structure Analysis of Single Gene Molecules by Psoralen Cross-Linking and Electron Microscopy. 1228:93–121.
16. Wolff T, Iyer NA, Rubin GM. Neuroarchitecture and Neuroanatomy of the Drosophila Central Complex : A GAL4-Based Dissection of Protocerebral Bridge Neurons and Circuits. 2015; 1037:997–1037.
17. Bang S, Lee S, Ko J, Son K, Tahk D. A Low Permeability Microfluidic Blood-Brain Barrier Platform with Direct Contact between Perfusable Vascular Network and Astrocytes. Sci Rep [Internet]. 2017; (December 2016):1–10. Available from: http://dx.doi.org/10.1038/s41598-017-07416-0
18. Lee S, Mogle JA, Jackson CL, Buxton OM. What ’ s not fair about work keeps me up : Perceived unfairness about work impairs sleep through negative work-to-family spillover. Soc Sci Res [Internet]. 2019; 81(March 2018):23–31. Available from: https://doi.org/10.1016/j.ssresearch.2019.03.002
19. Takahashi K, Yamanaka S. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. 2006; 2(3):663–76.
20. Lancaster MA, Renner M, Martin C, Wenzel D, Bicknell S, Hurles ME, et al. Europe PMC Funders Group Cerebral organoids model human brain development and microcephaly. 2014; 501(7467).
21. Madhavan M, Nevin ZS, Shick HE, Garrison E, Karl M, Clayton BLL, et al. HHS Public Access. 2019; 15(9):700–6.
22. Ormel PR, Sá RV De, Bodegraven EJ Van, Karst H, Harschnitz O, Sneeboer MAM, et al. Microglia innately develop within cerebral organoids. Nat Commun [Internet]. 2018; Available from: http://dx.doi.org/10.1038/s41467-018-06684-2
23. Shou Y, Liang F, Xu S, Li X. The Application of Brain Organoids : From Neuronal Development to Neurological Diseases. 2020; 8(October):1–10.
24. Ham DJ, Börsch A, Lin S, Thürkauf M, Weihrauch M, Reinhard JR, et al. The neuromuscular junction is a focal point of mTORC1 signaling in sarcopenia. Nat Commun [Internet]. (2020). Available from: http://dx.doi.org/10.1038/s41467-020-18140-1
25. Song L, Chen Y, Guo Q, Huang S, Guo X, Xiao D. Regulating the Golgi apparatus sorting of proteinase A to decrease its excretion in Saccharomyces cerevisiae. J Ind Microbiol Biotechnol [Internet]. 2019; 46(5):601–12. Available from: https://doi.org/10.1007/s10295-019-02147-9
26. Article V, Baufeld A, Vanselow J. A Tissue Culture Model of Estrogen-producing Primary Bovine Granulosa Cells. 2018; (September):1–7.
27. Thomsen J, Ramesh K, Sanders T, Bleich M, Melzner F. Calcification in a marginal sea – influence of seawater [ Ca 2 + ] and carbonate chemistry on bivalve shell formation. 2018; 1469–82.
28. Outcomes M. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. 2020;
29. Schaffhauser A, Payette S, Garneau M, Robert C. Soil paludification and Sphagnum bog initiation : the influence of indurated podzolic soil and fire. 2016;
30. Katsetos CD, Herman MM, Mo SJ. Class III  -Tubulin in Human Development and Cancer. 2003; 96(February):77–96.
31. Sarnat HB, Nochlin D, Born DE. Neuronal nuclear antigen ( NeuN ): a marker of neuronal maturation in the early human fetal nervous system 1. 1998; 20(3):88–94.
32. 81.pdf.
33. Vos KJ De, Grierson AJ, Ackerley S, Miller CCJ. Role of Axonal Transport in Neurodegenerative Diseases ∗. 2008;
34. Nimmrich V, Ebert U. Is Alzheimer ’ s Disease a Result of Presynaptic Failure ? Synaptic Dysfunctions Induced by Oligomeric ß-Amyloid. 2009; 12:1–12.
35. Zheng L, Roberg K, Jerhammar F, Marcusson J, Terman A. Autophagy of amyloid beta-protein in differentiated neuroblastoma cells exposed to oxidative stress. 2006; 394:184–9.
36. Tang-Schomer MD, White JD, Tien LW, Schmitt LI, Valentin TM, Graziano DJ, et al. Bioengineered functional brain-like cortical tissue. Proc Natl Acad Sci U S A. 2014; 111(38):13811–6.
37. D’Souza I, Schellenberg GD. Regulation of tau isoform expression and dementia. Biochim Biophys Acta - Mol Basis Dis. 2005; 1739(2):104–15.
38. Kim YH, Choi SH, Avanzo CD, Hebisch M, Bylykbashi E, Washicosky KJ, et al. disease. 2016; 10(7):985–1006.
39. Raja WK, Mungenast AE, Lin YT, Ko T, Abdurrob F, Seo J, et al. Self-organizing 3D human neural tissue derived from induced pluripotent stem cells recapitulate Alzheimer’s disease phenotypes. PLoS One. 2016; 11(9):1–18.
40. Games D, Adams D, Alessandrini R, Barbour R, Borthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Vol. 373, Nature. 1995. p. 523–7.
41. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Amyloid Plaques in Transgenic Mice. Science (80- ). 1996; 274(October):99–102.
42. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A. 1997; 94(24):13287–92.
43. Sturchler-Pierrat C, Staufenbiel M. Pathogenic mechanisms of Alzheimer’s disease analyzed in the APP23 transgenic mouse model. Ann N Y Acad Sci. 2000; 920:134–9.
44. Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, et al. Aβ42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006; 7(9):940–6.
45. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: Potential factors in amyloid plaque formation. J Neurosci. 2006; 26(40):10129–40.
46. Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, et al. A mouse model of amyloid β oligomers: Their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci. 2010; 30(14):4845–56.
47. Grueninger F, Bohrmann B, Czech C, Ballard TM, Frey JR, Weidensteiner C, et al. Phosphorylation of Tau at S422 is enhanced by Aβ in TauPS2APP triple transgenic mice. Neurobiol Dis [Internet]. 2010; 37(2):294–306. Available from: http://dx.doi.org/10.1016/j.nbd.2009.09.004
48. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (80- ). 2001; 293(5534):1487–91.
49. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. Neurobiol Aging. 2003; 24(8):1063–70.
50. Do Carmo S, Cuello AC. Modeling Alzheimer’s disease in transgenic rats. Mol Neurodegener [Internet]. 2013; 8(1):1. Available from: Molecular Neurodegeneration
51. Pan D, Zeng A, Jia L, Huang Y, Frizzell T, Song X. Early Detection of Alzheimer’s Disease Using Magnetic Resonance Imaging: A Novel Approach Combining Convolutional Neural Networks and Ensemble Learning. Front Neurosci. 2020; 14(May):1–19.
52. Cohen RM, Rezai-Zadeh K, Weitz TM, Rentsendorj A, Gate D, Spivak I, et al. A transgenic alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric Aβ, and frank neuronal loss. J Neurosci. 2013; 33(15):6245–56.
53. Leon WC, Canneva F, Partridge V, Allard S, Ferretti MT, Dewilde A, et al. A novel transgenic rat model with a full alzheimer’s - Like amyloid pathology displays pre - Plaque intracellular amyloid -β- Associated cognitive impairment. J Alzheimer’s Dis. 2010; 20(1):113–26.
54. Davis J, Xu F, Deane R, Romanov G, Previti M Lou, Zeigler K, et al. Early-onset and Robust Cerebral Microvascular Accumulation of Amyloid β-Protein in Transgenic Mice Expressing Low Levels of a Vasculotropic Dutch/Iowa Mutant Form of Amyloid β-Protein Precursor. J Biol Chem. 2004; 279(19):20296–306.
55. Kamp JA, Moursel LG, Haan J, Terwindt GM, Lesnik Oberstein SAMJ, Van Duinen SG, et al. Amyloid β in hereditary cerebral hemorrhage with amyloidosis-Dutch type. Rev Neurosci. 2014; 25(5):641–51.
56. Justyna W. 乳鼠心肌提取 {HHS} {Public} {Access}. Physiol Behav. 2017; 176(5):139–48.
57. Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature [Internet]. 2016; 537(7618):50–6. Available from: http://dx.doi.org/10.1038/nature19323
58. Forloni G, Balducci C. Alzheimer’s Disease, Oligomers, and Inflammation. J Alzheimer’s Dis. 2018; 62(3):1261–76.
59. Kim CS, Cha L, Sim M, Jung S, Chun WY, Baik HW, et al. Probiotic supplementation improves cognitive function and mood with changes in gut microbiota in community- dwelling older adults: A randomized, double-blind, placebo-controlled, multicenter trial. Journals Gerontol - Ser A Biol Sci Med Sci. 2021; 76(1):32–40.
60. Wang X, Sun G, Feng T, Zhang J, Huang X, Wang T, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression. Cell Res [Internet]. 2019; 29(10):787–803. Available from: http://dx.doi.org/10.1038/s41422-019-0216-x
61. Calsolaro V, Edison P. Neuroinflammation in Alzheimer’s disease: Current evidence and future directions. Alzheimer’s Dement [Internet]. 2016; 12(6):719–32. Available from: http://dx.doi.org/10.1016/j.jalz.2016.02.010
62. Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener. 2020; 9(1):1–12.
63. Sydenham E, Dangour AD, Lim WS. Omega 3 fatty acid for the prevention of cognitive decline and dementia. Sao Paulo Med J. 2012; 130(6):419.
64. Rolland Y, Barreto P de S, Maltais M, Guyonnet S, Cantet C, Andrieu S, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain lifestyle intervention on muscle strength in older adults: Secondary analysis of the multidomain alzheimer preventive trial (MAPT). Nutrients. 2019; 11(8).
65. Mcguinness B, Craig D, Bullock R, Malouf R, Passmore P. Statins for the treatment of dementia. Cochrane Database Syst Rev. 2014; 2014(7).
66. Dhakal S, Subhan M, Fraser JM, Gardiner K, Macreadie I. Simvastatin Efficiently Reduces Levels of Alzheimer’s Amyloid Beta in Yeast. Int J Mol Sci. 2019; 20(14):1–12.
67. Hampel H, Williams C, Etcheto A, Goodsaid F, Parmentier F, Sallantin J, et al. A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer’s disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study. Alzheimer’s Dement Transl Res Clin Interv. 2020; 6(1):1–15.
68. Marcinkowska M, Śniecikowska J, Fajkis N, Paśko P, Franczyk W, Kołaczkowski M. Management of Dementia-Related Psychosis, Agitation and Aggression: A Review of the Pharmacology and Clinical Effects of Potential Drug Candidates. CNS Drugs [Internet]. 2020; 34(3):243–68. Available from: https://doi.org/10.1007/s40263-020-00707-7
69. Kandiah N, Ong PA, Yuda T, Ng LL, Mamun K, Merchant RA, et al. Treatment of dementia and mild cognitive impairment with or without cerebrovascular disease: Expert consensus on the use of Ginkgo biloba extract, EGb 761®. CNS Neurosci Ther. 2019; 25(2):288–98.
70. Thota RN, Rosato JI, Dias CB, Burrows TL, Martins RN, Garg ML. Dietary supplementation with curcumin reduce circulating levels of glycogen synthase kinase-3Β and islet amyloid polypeptide in adults with high risk of type 2 diabetes and Alzheimer’s disease. Nutrients. 2020; 12(4).
71. Platero JL, Cuerda-Ballester M, Ibáñez V, Sancho D, Lopez-Rodríguez MM, Drehmer E, et al. The impact of coconut oil and epigallocatechin gallate on the levels of il-6, anxiety and disability in multiple sclerosis patients. Nutrients. 2020; 12(2):1–10.
72. Scheltens P, Vijverberg EGB. Aducanumab: Appropriate Use Recommendations. J Prev Alzheimer’s Dis. 2021; 8(4):412–3.